Plasma for cancer immunotherapy

Zhitong Chen Richard Wirz

Strategies to improve efficacy and reduce side effects of immune checkpoint blockade (ICB) therapy are clinically relevant. Here, we described a transdermal cold atmospheric plasma (CAP)-mediated ICB therapy. Local delivery of CAP through hollow-structured microneedles as microchannels promote the release of tumor- associated antigens by CAP. The subsequent T cell-mediated immune response can be augmented by the immune checkpoint inhibitors delivered via microneedles, resulting in enhanced local and systemic anticancer immunity. The synergism between CAP and ICB integrated with microneedles provides a platform technique for cancer treatment and other diseases in a minimally invasive manner. (www.pnas.org/cgi/doi/10.1073/pnas.1917891117)